<DOC>
	<DOC>NCT00605826</DOC>
	<brief_summary>The purpose of this study is to determine the effectiveness and safety of NASHA/Dx when used as an injectable bulking agent in the treatment of fecal incontinence. The study includes a 6-month blinded sham-controlled phase, followed by an open-label phase.</brief_summary>
	<brief_title>A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment of Fecal Incontinence</brief_title>
	<detailed_description>Subjects in the sham control group will have the option to receive open-label treatment with NASHA/Dx after the blinded phase.</detailed_description>
	<mesh_term>Fecal Incontinence</mesh_term>
	<criteria>1875 years of age, male or female Screening fecal incontinence severity score (CCFIS) Fecal incontinence episodes over a 14day period Failed conservative treatment for fecal incontinence Complete external sphincter disruption Significant anorectal disease Anorectal surgery within the last 12 months prior to the study Active Inflammatory Bowel Disease (IBD) Immunodeficiency or receiving immunosuppressive therapy Malignancies in remission for less than 2 years prior to the study Bleeding disorders or receiving anticoagulant therapy Chemotherapy within the last 12 months prior to the study Prior Pelvic radiotherapy Women who are pregnant or breastfeeding, or women of childbearing potential not practicing adequate contraception or planning to stop such contraception within the first year of the study Women within one year post partum Participation in any other clinical study within 3 month prior to the study Hypersensitivity to hyaluronic acid containing products Other severe conditions or in other ways unsuitable to participate according to investigator judgement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>